Aspen Aerogels, Inc.

As of June 30, 2026, Aspen Aerogels, Inc. carries a market capitalization of 526.15M, placing it among publicly traded companies globally. Its enterprise value stands at 499.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Aspen Aerogels, Inc.'s next confirmed earnings release is scheduled for February 18, 2027.

As of June 30, 2026, Aspen Aerogels, Inc. has 82.99M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.59, and the price-to-book ratio stands at 2.73.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 499.55M versus a market cap of 526.15M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Aspen Aerogels, Inc. maintains a current ratio of 2.52, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.01, indicating elevated leverage, while an interest coverage ratio of -6.91 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Aspen Aerogels, Inc. posted a negative return on equity (ROE) of -50.36, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -27.49, reflecting losses generated across the asset base. The company generates approximately 259,421.05 in revenue per employee across its workforce of 779.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.91 indicates how many times Aspen Aerogels, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Aspen Aerogels, Inc. recorded 863,000.00 in income tax expense. The company reported a pretax loss of -125.34M and -126.20M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on November 6, 2026, Aspen Aerogels, Inc.'s stock has gained approximately 19.46% over the past 52 weeks. The 50-day moving average sits at 5.23, while the 200-day moving average is 4.71.

Over the twelve months ended June 30, 2026, Aspen Aerogels, Inc. generated 202.09M in revenue and converted that into -126.20M in net income, yielding earnings per share of -1.53. EBITDA reached -80.11M, while operating income came in at -89.47M.

As of June 30, 2026, Aspen Aerogels, Inc. holds 151.71M in cash and equivalents against 125.11M in total debt, resulting in a net debt position of -60.51M. Total book value stands at 192.46M, with working capital of 149.85M providing operational flexibility.

Aspen Aerogels, Inc. produced 49.12M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Aspen Aerogels, Inc. posted a gross margin of 2.68, reflecting its pricing power and cost economics. The operating margin of -44.27 and net profit margin of -62.45 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 9.37, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 9.31, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Aspen Aerogels, Inc. shareholders.

As of June 30, 2026, Aspen Aerogels, Inc. has an Altman Z-Score of -2.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.